806 Genomic detection of melanoma, W. Wachsman et al. 10 Binder M, Schwarz M, Winkler A et al. Epiluminescence micros- copy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol 1995; 131:286–91. 11 Vestergaard M, Macaskill P, Holt P, Menzies SW. Dermoscopy compared to naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical set- ting. Br J Dermatol 2008; 159:669–76. 12 Skvara H, Teban L, Fiebiger M et al. Limitations of dermoscopy in the recognition of melanoma. Arch Dermatol 2005; 141:155–60. 13 Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dys- plastic nevi: a survey of fellows of the American Academy of Der- matology. J Am Acad Dermatol 2002; 46:674–82. 14 Haenssle HA, Krueger U, Vente C et al. Results from an observa- tional trial: digital epiluminescence microscopy increases the sensi- tivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol 2006; 126:980–5. 15 Marghoob AA, Swindle LD, Moricz CZ et al. Instruments and new technologies for the in vivo diagnosis of melanoma. J Am Acad Derma- tol 2003; 49:777–97. 16 Menzies SW. Cutaneous melanoma: making a clinical diagnosis, present and future. Dermatol Ther 2006; 19:32–9. 17 Vestergaad M, Menzies SW. Automated diagnostic instruments for cutaneous melanoma. Semin Cutan Med Surg 2008; 27:32–6. 18 Guitera P, Pellacani G, Longo C et al. In vivo confocal microscopy enhances secondary evaluation of melanocytic lesions. J Invest Derma- tol 2009; 129:131–8. 19 McGinnis KS, Lessin SR, Elder DE et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Der- matol 2002; 138:617–21. 20 Ferrara G, Argenyi Z, Argenziano G et al. The inﬂuence of clinical information in the histopathologic diagnosis of melanocytic skin neoplasms. PLoS ONE 2009; 4:e5375. 21 Morhenn VB, Chang EY, Rheins LA. A non-invasive method for quantifying and distinguishing inﬂammatory skin reactions. J Am Acad Dermatol 1999; 41:687–92. 22 Wong R, Tran V, Morhenn VB et al. Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inﬂamed skin. J Invest Dermatol 2004; 123:159–67. 23 Benson NR, Papenfuss J, Wong R et al. An analysis of select patho- genic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. J Invest Dermatol 2006; 126:2234–41. 24 Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-value Adjustment. New York: Wiley, 1993. 25 Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863–8. 26 Tamayo P, Slonim D, Mesirov J et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96:2907– 12. 27 Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat 2001; 29:1189–232. 28 Friedman JH. Stochastic gradient boosting. Comput Stat Data Anal 2002; 38:367–78. 29 Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recur- sive descent partition analysis. Clin Cancer Res 2004; 10:3291–300. 30 Naderi A, Teschendorff AE, Beigel J et al. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth fac- tor ⁄ nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 2007; 67:6725–36. 31 Berger Y, Bernasconi CC, Juillerat-Jeanneret L. Targeting the endo- thelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med 2006; 231:1111–19. 32 Wyman K, Atkins MB, Prieto V et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: signiﬁcant toxicity with no clinical efﬁcacy. Cancer 2006; 106:2005–11. 33 Nakajima TE, Yamada Y, Furuta K et al. Adiopokine levels and the risk of gastric cancer: a case–control study. J Clin Oncol 2008; 26 (Suppl.):4582 (Abstract). 34 Drochmans P. Etude au microscope e´lectronique du me´canisme de la pigmentation me´lanique. Arch Belg Dermatol Syphiligr 1960; 16:155–63. 35 Kubo A, Nagao K, Yokouchi M et al. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med 2009; 206:2937–46. 36 Torres-Cabala CA, Wang WL, Trent J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous ⁄ mucosal type. Mod Pathol 2009; 22:1446–56. 37 Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135–47. 38 Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mu- tations in primary melanomas. J Natl Cancer Inst 2003; 95:1878–90. Supporting Information Additional Supporting Information may be found in the online version of the article: Fig S1. Photomicrographs of a melanoma, not identiﬁed on initial histopathological evaluation, which was detected by the 17-gene melanoma classiﬁer. Table S1. Table of 312 differentially expressed genes between melanomas, naevi and normal skin specimens. Table S2. Table of 422 differentially expressed genes between melanomas and naevi. Table S3. Table of 168 genes identiﬁed by the TreeNet analysis in the training set. Table S4. Description of the 17-gene melanoma classiﬁer. Data S1. Details of strategy for melanoma class prediction modelling. Data S2. Assay of melanoma and nonmelanoma specimens by quantitative real-time reverse transcription–polymerase chain reaction using the 17-gene classiﬁer recapitulates micro- array results. Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article. BJD 2011 The Authors 2011 British Association of Dermatologists 2011 164, pp797–806